1. Executive Summary |
2. Global Diabetic Retinopathy Treatment Market Introduction |
2.1. Global Diabetic Retinopathy Treatment Market – Taxonomy |
2.2. Global Diabetic Retinopathy Treatment Market –Definitions |
2.2.1. Drug Type |
2.2.2. Route of Administration |
2.2.3. Distribution Channel |
3. Global Diabetic Retinopathy Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Diabetic Retinopathy Treatment Market Dynamic Factors - Impact Analysis |
3.6. Global Diabetic Retinopathy Treatment Market – Competition Landscape |
4. Global Diabetic Retinopathy Treatment Market, By Drug Type, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
4.1. Aflibercept |
4.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
4.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.1.3. Market Opportunity Analysis |
4.2. Ranibizumab |
4.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
4.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.2.3. Market Opportunity Analysis |
4.3. Corticosteroids |
4.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
4.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.3.3. Market Opportunity Analysis |
4.4. Others |
4.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
4.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.4.3. Market Opportunity Analysis |
5. Global Diabetic Retinopathy Treatment Market Forecast, By Route of Administration, 2017-2021 and Forecast, 2021 – 2027 (Revenue, USD Mn) |
5.1. Oral |
5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Parenteral |
5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Others |
5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6. Global Diabetic Retinopathy Treatment Market, By Distribution Channel, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
6.1. HOSPITAL PHARMACIES |
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. RETAIL PHARMACIES |
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. ONLINE PHARMACIES |
6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Diabetic Retinopathy Treatment Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
7.1. North America |
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia-Pacific |
7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Latin America |
7.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Middle East and Africa |
7.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Global Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel and Region, 2022-2028 |
8. North America Diabetic Retinopathy Treatment MarketAnalysis,2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
8.1. By Drug Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
8.1.1. Aflibercept |
8.1.2. Ranibizumab |
8.1.3. Corticosteroids |
8.1.4. Others |
8.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
8.2.1. Oral |
8.2.2. Parenteral |
8.2.3. Others |
8.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
8.3.1. HOSPITAL PHARMACIES |
8.3.2. RETAIL PHARMACIES |
8.3.3. ONLINE PHARMACIES |
8.4. Country Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
8.4.1. USA |
8.4.2. Canada |
8.5. North America Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2022-2028 |
8.6. North America Diabetic Retinopathy Treatment Market Dynamics – Trends |
9. Europe Diabetic Retinopathy Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
9.1. By Drug Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Aflibercept |
9.1.2. Ranibizumab |
9.1.3. Corticosteroids |
9.1.4. Others |
9.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
9.2.1. Oral |
9.2.2. Parenteral |
9.2.3. Others |
9.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
9.3.1. HOSPITAL PHARMACIES |
9.3.2. RETAIL PHARMACIES |
9.3.3. ONLINE PHARMACIES |
9.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
9.4.1. Germany |
9.4.2. UK |
9.4.3. France |
9.4.4. Spain |
9.4.5. Italy |
9.4.6. Russia |
9.4.7. Poland |
9.4.8. Rest of Europe |
9.5. Europe Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2022-2028 |
9.6. Europe Diabetic Retinopathy Treatment Market Dynamics – Trends |
10. Asia-Pacific Diabetic Retinopathy Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
10.1. By Drug Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Aflibercept |
10.1.2. Ranibizumab |
10.1.3. Corticosteroids |
10.1.4. Others |
10.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.2.1. Oral |
10.2.2. Parenteral |
10.2.3. Others |
10.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. HOSPITAL PHARMACIES |
10.3.2. RETAIL PHARMACIES |
10.3.3. ONLINE PHARMACIES |
10.4. Country Analysis2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Japan |
10.4.2. China |
10.4.3. India |
10.4.4. ASEAN |
10.4.5. Australia & New Zealand |
10.4.6. Rest of Asia-Pacific |
10.5. Asia-Pacific Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2022-2028 |
10.6. Asia-Pacific Diabetic Retinopathy Treatment Market Dynamics – Trends |
11. Latin America Diabetic Retinopathy Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
11.1. By Drug Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Aflibercept |
11.1.2. Ranibizumab |
11.1.3. Corticosteroids |
11.1.4. Others |
11.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.2.1. Oral |
11.2.2. Parenteral |
11.2.3. Others |
11.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. HOSPITAL PHARMACIES |
11.3.2. RETAIL PHARMACIES |
11.3.3. ONLINE PHARMACIES |
11.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Brazil |
11.4.2. Mexico |
11.4.3. Argentina |
11.4.4. Rest of Latin America |
11.5. Latin America Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2022-2028 |
11.6. Latin America Diabetic Retinopathy Treatment Market Dynamics – Trends |
12. Middle East and Africa Diabetic Retinopathy Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
12.1. By Drug Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Aflibercept |
12.1.2. Ranibizumab |
12.1.3. Corticosteroids |
12.1.4. Others |
12.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.2.1. Oral |
12.2.2. Parenteral |
12.2.3. Others |
12.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. HOSPITAL PHARMACIES |
12.3.2. RETAIL PHARMACIES |
12.3.3. ONLINE PHARMACIES |
12.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Gulf Cooperation Council (GCC) Countries |
12.4.2. Israel |
12.4.3. South Africa |
12.4.4. Rest of MEA |
12.5. MEA Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2022-2028 |
12.6. MEA Diabetic Retinopathy Treatment Market Dynamics – Trends |
13. Global Diabetic Retinopathy Treatment - Pipeline Drug Analysis |
13.1. Global Diabetic Retinopathy Treatment Disease Epidemiology |
13.2 Global Diabetic Retinopathy Treatment, Pipeline Drugs Assessment |
13.3. Global Diabetic Retinopathy Treatment, Pipeline Drugs Assessment - Sponsors/Companies |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, Route of Administration& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. Regeneron Pharmaceuticals |
14.2.2. Novartis AG |
14.2.3. Genentech |
14.2.4. Novartis AG |
14.2.5. Bayer AG |
14.2.6. Oxurion |
14.2.7. OccuRx |
14.2.8. AptaBio Therapeutics |
14.2.9. Kodiak Sciences |
14.2.10. RemeGen |
14.2.11. F. Hoffman-La-Roche AG. |
14.2.12. Grifols S.A. |
15. Research Methodology |
16. Key Assumptions and Acronymsc |
2021 is the base year and 2028 is the forecast year.
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.